# PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual

> **NCT01800305** · PHASE1 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 150 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Pegylated rhEPO
- **DRUG:** EPIAO®

## Key facts

- **NCT ID:** NCT01800305
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2015-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01800305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01800305, "PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT01800305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*